NCT07154485 · Phase 2 · NOT YET RECRUITING
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
This Phase 2 trial is testing NS101, an experimental drug given by IV infusion, against a placebo in people with semantic variant frontotemporal dementia — a type of FTD that primarily affects language and word meaning. Researchers are measuring safety, how the drug behaves in the body, and early signs of whether it works. Phase 2 means the drug is still in early testing and is not proven or approved.
You may qualify if
- Participants diagnosed at screening with mild to moderate frontotemporal dementia, semantic variant (svFTD), defined by a CDR® Plus NACC FTLD Sum of Boxes (SOB) score between 4.5 and 15.5.
- Participants confirmed to be amyloid-negative based on Amyloid PET scan or CSF results within the past 36 months.
You're excluded if
- Participants with other degenerative brain diseases as determined by the investigator
- Participants with other neurological disorders and uncontrolled acute disease
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-09-04